Optogenetic CTL Activation for Light-Controlled Tumor Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancer, such as those targeting T cell activation, often induce severe side effects due to uncontrolled T cell activation in both tumor and healthy tissues, necessitating precise spatiotemporal control to limit immune-related adverse events.
Innovation Solution
A light-controlled molecular system comprising a recombinant protein with a variable domain of an antibody fused to a photoactivable agent and a tumor-specific antigen antibody, allowing controlled tumor cell lysis by cytotoxic T lymphocytes (CTLs) using light.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapies targeting T cell activation are used to treat cancer, then tumor cell killing efficacy is improved, but immune-related adverse events occur due to uncontrolled T cell activation in healthy tissues
Solution Approach 1:
The patent applies preliminary action by administering the bispecific T cell engager molecule and photosensitizer to the patient before light activation. This allows the molecules to accumulate at the tumor site and bind to T cells and tumor antigens in advance, so that when light is applied, the T cell activation occurs only at the pre-positioned site, preventing systemic activation and immune-related adverse events
Solution Approach 2:
The patent uses light as an intermediary to control T cell activation. The photosensitizer converts light energy into a form that activates the bispecific engager molecule, which then mediates controlled T cell engagement with tumor cells. This intermediary mechanism allows spatial and temporal control, activating T cells only when and where light is applied, rather than causing uncontrolled systemic activation
2Object-affected harmful factors
If precise spatiotemporal control of T cell activation is implemented using light, then immune-related adverse events are reduced, but treatment complexity increases due to additional light delivery requirements
Solution Approach 1:
The patent segments the treatment into distinct modular components: the bispecific T cell engager molecule, the photosensitizer, and the light delivery system. This segmentation allows each component to be optimized independently and facilitates precise control of T cell activation in space and time, reducing immune-related adverse events while maintaining manageable treatment complexity through modular design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise spatiotemporal control of tumor cell killing by CTLs, reducing the risk of immune-related adverse events and enhancing the efficacy of cancer treatment.
Implementation Method 1
a light-controlled molecular system comprising: a. at least one recombinant protein comprising a variable domain of an antibody that is fused at its c-terminal end to a compound that can interact with a photoactivable agent in a light-dependent manner
Data Source
AI summary
The inventors have developed a new system of optogenetics-based recombinant system allowing to target tumor cells to control in space and time tumor cell lysis by cytotoxic T lymphocytes (CTLs) with light. To do so, they have coupled tumor-specific antigen antibody to a photoreceptor protein that can bind an optogenetic domain linked to a Fab fragment derived from an agonistic antibody targeting the TCR. They demonstrated that these new system allow the spatio-temporal control of the tumor cell killing by CTLs in vitro, in response to light. The present invention relates to methods of activating on demand an immune cell or a plurality of immune cells, and methods for treating cancer.